A new study by Oxford University researchers shows that the new strain of “Omicron” avoids neutralizing antibodies produced by two doses of Pfizer and Astraznka vaccines, so injecting two doses of these vaccines does not prevent the strain.
A new study by Oxford University researchers shows that injecting two doses of Pfizer or Astrazenka vaccine to prevent Covid-19 disease may protect against infection. Due to the amicron strain is not enough.
These data do not provide any indication of protection against severe disease, and also show that two doses are not enough to prevent amicron infection in most people.
As scientists compete for more information on the newly emerged strain of the coronavirus, called emicron, laboratory studies have begun to provide insights into how this strain reacts to the virus to antibodies or antibodies to the vaccine.
This new study, which is available as a pre-published article and has not yet been peer-reviewed or published in a scientific journal, collects how antibodies produced after injecting two doses of the Covid-19 vaccine into an amicron-type virus. Has been looking at an infected case in the UK.
The strain was tested on blood samples taken from people about four weeks after the second dose of Pfizer or Astraznka vaccine. The researchers found that injecting two doses of these vaccines had little neutralizing effect on amicron and that fewer antibody responses were produced in response to the virus.
In fact, injecting two doses of Astraznka vaccine showed the worst performance, and this study showed that the rate of virus neutralization reached below the detectable range in all but one sample.
The Pfizer vaccine, however, performed much better, with only one sample falling below the detectable range. However, the researchers still saw an average of 30-fold reduction in the neutralizing effect of the two doses of the Pfizer vaccine compared to the antibody responses observed with the previous strain of the virus.
The researchers cautiously note that these findings do not necessarily indicate that injecting two doses of each of these vaccines is effective in preventing severe Covid-19 disease, hospitalization, or death. Antibody responses are only part of the immune system’s response to a viral threat, and while antibody responses generally play an important role in preventing primary infection, other immune cells kill and clear the virus as soon as the virus is inhibited. They enter the cycle.
These data suggest that the emicron strain leads to a higher rate of infection in people who have only been vaccinated with two doses. Although the severity of the disease caused by emicron is still unclear, researchers emphasize that more cases, even if they lead to a milder disease in general, will inevitably lead to a greater burden on health care systems.
“While there is no evidence of an increased risk of severe infection or death from this strain of the virus in vaccinated populations, we need to be cautious as more cases continue to occur,” said lead author Gavin Scritton. It puts a significant burden on health care systems.
This study does not offer new insights into the effect of injecting three doses of the vaccine against the Amicron strain, but the researchers believe that boosting the dose significantly increases the neutralizing antibody response. In addition, a recent study published by Pfizer provides valuable data that supports this hypothesis.
These new findings somewhat confirm recent attempts to inject a third dose of the vaccine into all adults in the UK as soon as three months after the second dose has been given.
In Britain, widespread use of the Astraznka vaccine and the growing number of cases of Amicron have prompted Prime Minister Boris Johnson to declare a state of emergency. The British government is seeking to inject a third dose into tens of millions by the end of this year.